atherothrombosis

ath·er·o·throm·bo·sis

(ath'er-ō-throm-bō'sis),
Thrombus formation in an atheromatous vessel.

atherothrombosis

[ath′ərō′thrombō′sis]
a condition in which a thrombus originates in an atheromatous blood vessel.

atherothrombosis

Clotting of blood within an artery at the site of an atheromatous plaque. Atherothrombosis is the principal cause of death in the Western world because of its complications—heart attack, stroke, limb gangrene, and ischaemic organ disease including dementia. Antiplatelet therapy to prevent atherothrombosis can reduce vascular disease mortality by 15 per cent and non-fatal vascular events by 30 per cent.
References in periodicals archive ?
sup][35],[36],[37] Further research is required to explore the effect, pathogenesis, and preventive measures of the potential risk factors, including concomitant factors, related to atherothrombosis in CVT recurrence.
The lack of a protective effect from B vitamin supplementation is disappointing, yet the error of this reductionist approach to vascular disease should not be compounded by the erroneous reductionist conclusion that homocysteine does not directly promote atherothrombosis.
The 4-year results from the Reduction of Atherothrombosis for Continued Health (REACH) registry also added new evidence on the role of polyvascular disease, the study's "most potent predictor of future ischemic events.
Oxidant stress: a key determinant of atherothrombosis.
The risk rose to as high as 25 percent for those with clinical evidence of atherothrombosis in multiple arteries and a history of heart attack or stroke.
34] Increasing hs-CRP level suggests that the chronic inflammation that leads the progression of atherosclerosis and atherothrombosis is a causative factor for CHD.
12] Nonstandard abbreviations: NHLBI, National Heart, Lung, and Blood Institute; AIM-HIGH, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes (study).
REACH (Reduction of Atherothrombosis for Continued Health) is the largest worldwide registry of patients with all types of atherothrombotic disease.
BG Medicine launched the HRP Initiative in 2006 to advance the understanding, recognition and management of atherothrombosis, the underlying disease process that may lead to heart attack or stroke.
4,5,6,7) MPV is a new and independent risk factor for atherothrombosis.
CRP is a valid marker of cardiovascular risk, and mounting data support a role for CRP in atherothrombosis (1-4).